Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Letter Commentary & Co-Mentions | Period / Date | Action |
|---|---|---|---|
“Kyverna, along with Fund holdings Cabaletta Bio and Cartesian Therapeutics, are all trying to prove out this approach, which could potentially apply to larger autoimmune markets, including myasthenia gravis and multiple sclerosis. While challenges to...” | Q2 2026 Jul 8, 2026 | Preview | |
“Kyverna, along with Fund holdings Cabaletta Bio and Cartesian Therapeutics, are all trying to prove out this approach, which could potentially apply to larger autoimmune markets, including myasthenia gravis and multiple sclerosis. Kyverna's stiff person...” | Q2 2026 Jul 8, 2026 | Preview |
Read unredacted commentary excerpts, portfolio weight disclosures, and high-conviction theses from hedge fund managers discussing $CABA.(1 additional institutional mentions locked).
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
